Quetiapin in der Behandlung der akuten Manie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Quetiapin ist ein atypisches Neuroleptikum, das sowohl Positiv- als auch Negativsymptome schizophrener Erkrankungen günstig beeinflusst, ohne extrapyramidalmotorische Nebenwirkungen auszulösen oder die Kognition ungünstig zu beeinflussen. Es gibt mittlerweile mehrere plazebokontrollierte, doppelblinde Studien, Fallberichte und offene Studien zum Einsatz von Quetiapin bei akuten Manien und therapierefraktären bipolaren Erkrankungen bei veschiedenen Patientengruppen. Insgesamt scheint Quetiapin stimmungsstabilisierende Eigenschaften bei einem günstigen Verträglichkeitsprofil zu haben.

Abstract

Quetiapine is an atypical antipsychotic that has shown efficacy in the treatment of positive and negative symptoms in schizophrenia without causing extrapyramidal symptoms (EPS). To date, there are two monotherapy and two combination therapy studies with a double blind, placebo-controlled design on the use of quetiapine in mania. Several open studies and case reports support the results of the controlled trials suggesting that quetiapine is effective in treating the broad spectrum of manic symptoms and is tolerated well.

Literatur

• 1 Kessler R C, McGonagle K AZS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey.  Arch Gen Psychiatry. 1994;  51 8-19
  PubMedGoogle Scholar
• 2 Coryell W, Leon A C, Turvey C, Akiskal H, Mueller T I, Endicott J. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study.  J Affect Disord. 2001;  67 (1 - 3) 79-88
  CrossrefPubMedGoogle Scholar
• 3 Fennig S, Bromet E J, Karant M T, Ram R, Jandorf L. Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients with affective disorder.  J Affect Disord. 1996;  37 (1) 23-29
  CrossrefPubMedGoogle Scholar
• 4 Swann A C, Janicak P L, Calabrese J R, Bowden C L, Dilsaver S C, Morris D D. Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomised clinical trial participants.  J Affect Disord. 2001;  67 (1 - 3) 123-132
  CrossrefPubMedGoogle Scholar
• 5 Goodwin F K, Jamison K R. Manic-depressive illness. New York; Oxford University Press 1990
  Google Scholar
• 6 Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.  J Clin Psychopharmacol. 1998;  18 (6) 455-460
  CrossrefPubMedGoogle Scholar
• 7 Tohen M, Hennen J, Zarate Jr C M, Baldessarini R J, Strakowski S M, Stoll A L. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features.  Am J Psychiatry. 2000;  157 (2) 220-228
  CrossrefPubMedGoogle Scholar
• 8 Maj M, Pirozzi R, Bartoli L, Magliano L. Long-term outcome of lithium prophylaxis in bipolar disorder with mood-incongruent psychotic features: a prospective study.  J Affect Disord. 2002;  71 (1 - 3) 195-198
  CrossrefPubMedGoogle Scholar
• 9 Nasrallah H A, Churchill C M, Hamdan-Alla G A. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia.  Am J Psychiatry. 1988;  145 (11) 1455-1456
  PubMedGoogle Scholar
• 10 Mukherjee S, Rosen A M, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients.  Arch Gen Psychiatr. 1986;  43 (4) 342-346
  PubMedGoogle Scholar
• 11 Arvanitis L A, Miller B G. Multiple fixed doses of seroquel in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo.  Biol Psychiatry. 1997;  42 233-246
  CrossrefPubMedGoogle Scholar
• 12 Small J G, Hirsch S R, Arvanitis L A. Quetiapine in patients with schizophrenia: a high and low dose double-blind comparison with placebo.  Arch Gen Psychiatry. 1997;  54 (5) 549-557
  CrossrefPubMedGoogle Scholar
• 13 McIntyre R M, Brecher M, Paulsson B. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomized, parallel group, placebo-controlled trial. European Psychopharmacol 2005, im Druck
  Google Scholar
• 14 Bowden C L, Grunze H, Mullen J. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.  J Clin Psychiatry. 2005;  66 111-121
  CrossrefPubMedGoogle Scholar
• 15 Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine as monotherapy for mania associated with bipolar disorder: combined analysis of two international, randomised, double-blind, placebo-controlled studies.  Curr Med Res Opinion. 2005;  21 923-934
  PubMedGoogle Scholar
• 16 Sachs G, Chengappa K N, Suppes T, Mullen J A, Brecher M, Devine M. et al . Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind placebo-controlled study.  Bipolar Disord. 2004;  6 (3) 213-223
  CrossrefPubMedGoogle Scholar
• 17 Yatham L N, Paulsson B, Mullen J, Vagero A M. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.  J Clin Psychopharmacol. 2004;  24 (6) 599-606
  PubMedGoogle Scholar
• 18 Bahk W M, Lee K U, Chae J H, Pae C U, Jun T, Kim K S. Open label study of the effect of amantadine on weight gain induced by olanzapine.  Psychiatry Clin Neurosci. 2004;  58 (2) 163-167
  CrossrefPubMedGoogle Scholar
• 19 Sajatovic M, Brescan D W, Perez D E, DiGiovanni S K, Hattab H, Ray J B. et al . Quetiapine alone and added to a mood stabilizer for serious mood disorders.  J Clin Psychiatry. 2001;  62 (9) 728-732
  PubMedGoogle Scholar
• 20 Dunayevich E, Tugrul K C, Strakowski S M. Quetiapine in the treatment of mania. International Congress on Schizophrenia Research. Whistler, Colorado; May 2001
  Google Scholar
• 21 Dunayevich E, Strakowski S M. Quetiapine for treatment-resistant mania.  Am J Psychiatry. 2000;  157 1341
  CrossrefPubMedGoogle Scholar
• 22 Altamura C, Madaro D, Salvadori D. Quetiapine in acute mania: a case report (with a six-month follow-up).  Int J Psychiatry Clin Pract. 2001;  5 283-285
  PubMedGoogle Scholar
• 23 Suppes T, McElroy S L, Keck P E, Altshuler L, Frye M A, Grunze H. Use of quetiapine in bipolar disorder: a case series with prospective evaluation.  Int Clin Psychopharmacol. 2004;  19 (3) 173-174
  PubMedGoogle Scholar
• 24 Ozcan M E, Kaya B, Polat R. Weight gain and improvement with quetiapine in bipolar-I disorder: a case report.  Prog Neuropsychopharmacol Biol Psychiatry. 2004;  28 (2) 413-415
  CrossrefPubMedGoogle Scholar
• 25 Zarate Jr C A, Rothschild A, Fletcher K E, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders.  J Clin Psychiatry. 2000;  61 (3) 185-189
  PubMedGoogle Scholar
• 26 Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in the elderly with psychotic diosrders.  J Geriatr Psychiatry Neurol. 2000;  13 (1) 18-32
  PubMedGoogle Scholar
• 27 Pae C U, Lee K U, Kim J J, Lee C U, Bahk W M, Lee S J. Switching to quetiapine in patients with acute mania who were intolerant to risperidone.  Hum Psychopharmacol. 2004;  19 47-51
  PubMedGoogle Scholar
• 28 Chisholm K, Dennehy E B, Suppes T. Clinical response to quetiapine add-on for treatment of refractory bipolar disorder. Pittsburgh; Fourth International Conference on bipolar disorder 2001
  Google Scholar
• 29 Ghaemi S N, Katzow J J. The use of quetiapine for treatment-resistant bipolar disorder: a case series.  Ann Clin Psychiatry. 2000;  11 (3) 137-140
  PubMedGoogle Scholar

Prof. Dr. med. habil. Peter Bräunig

Klinik für Psychiatrie und Psychotherapie · Vivantes Humboldt-Klinikum Berlin · Akademisches Lehrkrankenhaus der Charité · Universitätsmedizin Berlin

Am Nordgraben 2

13509 Berlin

Email: peter.braeunig@vivantes.de